Frelin Lars, Wahlström Therese, Tucker Amy E, Jones Joyce, Hughes Janice, Lee Byung O, Billaud Jean-Noel, Peters Cory, Whitacre David, Peterson Darrell, Milich David R
Vaccine Research Institute of San Diego, 3030 Bunker Hill Street, Suite 300, San Diego, CA 92109, USA.
J Virol. 2009 Feb;83(3):1379-92. doi: 10.1128/JVI.01902-08. Epub 2008 Nov 12.
Hepatitis B virus (HBV) expresses two structural forms of the nucleoprotein, the intracellular nucleocapsid (hepatitis core antigen [HBcAg]) and the secreted nonparticulate form (hepatitis e antigen [HBeAg]). The aim of this study was to evaluate the ability of HBcAg- and HBeAg-specific genetic immunogens to induce HBc/HBeAg-specific CD4(+)/CD8(+) T-cell immune responses and the potential to induce liver injury in HBV-transgenic (Tg) mice. Both the HBcAg- and HBeAg-specific plasmids primed comparable immune responses. Both CD4(+) and CD8(+) T cells were important for priming/effector functions of HBc/HBeAg-specific cytotoxic T-lymphocyte (CTL) responses. However, a unique two-step immunization protocol was necessary to elicit maximal CTL priming. Genetic vaccination did not prime CTLs in HBe- or HBc/HBeAg-dbl-Tg mice but elicited a weak CTL response in HBcAg-Tg mice. When HBc/HBeAg-specific CTLs were adoptively transferred into HBc-, HBe-, and HBc/HBeAg-dbl-Tg mice, the durations of the liver injury and inflammation were significantly greater in HBeAg-Tg recipient mice than in HBcAg-Tg mice. Importantly, liver injury in HBc/HBeAg-dbl-Tg mice was similar to the injury observed in HBeAg-Tg mice. Loss of HBeAg synthesis commonly occurs during chronic HBV infection; however, the mechanism of selection of HBeAg-negative variants is unknown. The finding that hepatocytes expressing wild-type HBV (containing both HBcAg and HBeAg) are more susceptible to CTL-mediated clearance than hepatocytes expressing only HBcAg suggest that the HBeAg-negative variant may have a selective advantage over wild-type HBV within the livers of patients with chronic infection during an immune response and may represent a CTL escape mutant.
乙型肝炎病毒(HBV)表达两种核蛋白结构形式,即细胞内核衣壳(乙型肝炎核心抗原[HBcAg])和分泌的非颗粒形式(乙型肝炎e抗原[HBeAg])。本研究的目的是评估HBcAg和HBeAg特异性基因免疫原诱导HBc/HBeAg特异性CD4(+)/CD8(+) T细胞免疫反应的能力,以及在HBV转基因(Tg)小鼠中诱导肝损伤的可能性。HBcAg和HBeAg特异性质粒引发的免疫反应相当。CD4(+)和CD8(+) T细胞对于HBc/HBeAg特异性细胞毒性T淋巴细胞(CTL)反应的启动/效应功能都很重要。然而,需要一种独特的两步免疫方案来引发最大程度的CTL启动。基因疫苗接种在HBe或HBc/HBeAg双转基因小鼠中不能启动CTL,但在HBcAg转基因小鼠中引发了微弱的CTL反应。当将HBc/HBeAg特异性CTL过继转移到HBc、HBe和HBc/HBeAg双转基因小鼠中时,HBeAg转基因受体小鼠的肝损伤和炎症持续时间明显长于HBcAg转基因小鼠。重要的是,HBc/HBeAg双转基因小鼠的肝损伤与HBeAg转基因小鼠中观察到的损伤相似。HBeAg合成的丧失在慢性HBV感染期间通常会发生;然而,HBeAg阴性变异体的选择机制尚不清楚。表达野生型HBV(同时含有HBcAg和HBeAg)的肝细胞比仅表达HBcAg的肝细胞更容易受到CTL介导的清除,这一发现表明,在免疫反应期间,HBeAg阴性变异体在慢性感染患者的肝脏中可能比野生型HBV具有选择性优势,并且可能代表一种CTL逃逸突变体。